From MOTS-c’s ability to improve insulin sensitivity and prevent diet-induced obesity to ADM2′s potential role in glucose regulation through cAMP signaling, and its elevated levels in thyroid cancer patients, microproteins offer promising new avenues for therapeutic intervention aimed at maintaining glucose homeostasis and reducing the burden of NCDs. This evidence concerns the gene ADM2 and thyroid cancer.